Charles Schwab Investment Management Inc. Increases Stock Position in Liquidia Co. (NASDAQ:LQDA)

Charles Schwab Investment Management Inc. boosted its position in shares of Liquidia Co. (NASDAQ:LQDA - Free Report) by 9.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 428,570 shares of the company's stock after buying an additional 38,313 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.51% of Liquidia worth $5,040,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Whitefort Capital Management LP boosted its stake in shares of Liquidia by 119.8% during the 3rd quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company's stock worth $17,020,000 after acquiring an additional 927,546 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Liquidia by 855.3% in the third quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company's stock valued at $2,354,000 after purchasing an additional 210,753 shares during the period. Anson Funds Management LP purchased a new stake in shares of Liquidia in the third quarter valued at approximately $1,764,000. BNP Paribas Financial Markets increased its position in shares of Liquidia by 735.1% in the third quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company's stock valued at $1,402,000 after buying an additional 123,402 shares in the last quarter. Finally, Acuta Capital Partners LLC acquired a new position in shares of Liquidia during the 3rd quarter worth approximately $735,000. Hedge funds and other institutional investors own 64.54% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on LQDA. Needham & Company LLC lifted their price target on shares of Liquidia from $19.00 to $25.00 and gave the company a "buy" rating in a research note on Thursday, March 20th. HC Wainwright reiterated a "buy" rating and issued a $29.00 target price on shares of Liquidia in a research report on Thursday, March 20th. Wells Fargo & Company initiated coverage on shares of Liquidia in a research report on Friday, December 20th. They set an "overweight" rating and a $20.00 price target for the company. Finally, Scotiabank reiterated an "outperform" rating on shares of Liquidia in a report on Thursday, March 20th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Liquidia currently has a consensus rating of "Buy" and a consensus price target of $26.63.

Remove Ads

Insiders Place Their Bets

In related news, General Counsel Russell Schundler sold 16,393 shares of the company's stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $193,109.54. Following the completion of the sale, the general counsel now owns 573,478 shares of the company's stock, valued at approximately $6,755,570.84. This represents a 2.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Roger Jeffs sold 22,343 shares of Liquidia stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $263,200.54. Following the transaction, the chief executive officer now directly owns 1,019,177 shares in the company, valued at $12,005,905.06. This trade represents a 2.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 71,245 shares of company stock valued at $843,326 in the last three months. 30.10% of the stock is currently owned by insiders.

Liquidia Trading Down 1.0 %

LQDA stock traded down $0.15 during mid-day trading on Friday, reaching $15.09. The company's stock had a trading volume of 588,560 shares, compared to its average volume of 936,085. The company's 50 day moving average is $15.10 and its two-hundred day moving average is $12.42. Liquidia Co. has a fifty-two week low of $8.26 and a fifty-two week high of $16.81. The stock has a market cap of $1.29 billion, a PE ratio of -9.26 and a beta of 0.07.

Liquidia (NASDAQ:LQDA - Get Free Report) last posted its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.08). The company had revenue of $2.92 million during the quarter, compared to analysts' expectations of $4.60 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. On average, analysts forecast that Liquidia Co. will post -1.51 earnings per share for the current fiscal year.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).